Safety, Tolerability, and Pharmacokinetics of CG2001 in Chinese Adult Male Subjects With Androgenetic Alopecia: A Randomized, Double-Blind, Placebo-Controlled, Single- and Multi-Dose, Phase 1 Clinical Study

This phase 1 clinical study assessed the safety, tolerability, and pharmacokinetics of CG2001, a topical foam combining minoxidil and finasteride, in 44 Chinese male subjects with androgenetic alopecia. The study concluded that CG2001 was safe and well-tolerated, with no serious adverse events and only mild adverse reactions like transient dermatitis. The topical application resulted in significantly lower systemic exposure to finasteride compared to oral administration, potentially reducing sexual side effects. Both minoxidil and finasteride reached steady state after 7 days of use. The findings support further clinical development of CG2001 as a promising alternative treatment for androgenetic alopecia.